Takeda Italia company information, Employees & Contact Information

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors Business Wire

Mass. pharmaceutical company announces new round of layoffs Boston.com

Bristol Myers, Takeda to pool data for AI-based drug discovery Reuters

Massachusetts’ largest biopharma employer to lay off 137 people in Cambridge MassLive

Aiming to enhance regulatory submissions with GenAI | Takeda Stories Takeda Pharmaceuticals

Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus Fierce Biotech

Takeda Pharmaceutical Co. 2025: Going global PharmaLive

Biopharmaceutical company Takeda to lay off more than 130 employees in Cambridge Wicked Local

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression Yahoo Finance

Takeda Announces Decision to Discontinue Cell Therapy Research Pharmaceutical Executive

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise Seeking Alpha

Alkermes, Takeda show encouraging data on narcolepsy drugs | STAT statnews.com

Takeda lays off 137 Mass. workers as it halts cell therapy work The Business Journals

How Takeda's CEO transformed the company into a global pharma powerhouse CNBC

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership Reuters

UPDATED: Takeda lays off 137 US staff as part of retreat from cell therapy Fierce Biotech

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 Business Wire

Takeda Pharmaceutical to exit cell therapy research Reuters

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit Business Wire

Japan's Takeda weighs India for global trials to speed up drug launches Reuters

Takeda Vietnam Pharmaceuticals and Dentsu Redder Spotlight Dengue Fever in Campaign Branding in Asia

Takeda Announces New Assignments of Directors Business Wire

Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality BioSpace

Takeda Discontinues Cell Therapy Efforts to Refocus Investments TipRanks

Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion Yahoo Finance

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 Business Wire

Office cluster with Takeda HQ refinances for $1.3B The Business Journals

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries Business Wire

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration Business Wire

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran Business Wire

Takeda bets on narcolepsy drug for new blockbuster franchise The Business Journals

Takeda Careers, Perks + Culture Built In

Lobbying Update: $1,520,000 of TAKEDA PHARMACEUTICALS AMERICA INC lobbying was just disclosed Quiver Quantitative

Lobbying Update: $1,570,000 of TAKEDA PHARMACEUTICALS AMERICA INC lobbying was just disclosed Quiver Quantitative

Takeda Report Highlights Company’s Commitment to Cutting-Edge Science, Putting Patients First CSRwire

AI in Biopharma Innovation and Regulatory Challenges – with Nishtha Jain of Takeda Pharmaceuticals Emerj Artificial Intelligence Research

Takeda to seek approval of new kind of narcolepsy drug after study data BioPharma Dive

Takeda, largest biopharma employer in Mass., plans more layoffs The Boston Globe

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 Business Wire

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 Business Wire

Takeda faces another 'pay-for-delay' antitrust lawsuit, this one from CVS over heartburn drug Dexilant Fierce Pharma

Cosmo Pharmaceuticals Extends Global Supply Agreement with Takeda TipRanks

Takeda Partners with VELA to Launch Wind-Powered Medicine Transport Across the Atlantic Pharmaceutical Commerce

Takeda partners with Salesforce for AI-powered healthcare engagement FirstWord Pharma

Takeda Pharmaceutical Reports Q1 2025 Earnings with Profit Growth TipRanks

Takeda Pharmaceutical’s 149th Shareholders Meeting Approves Key Resolutions TipRanks

Hackers demand $75,000 for data allegedly stolen from Takeda Cybernews

What's Going On With Takeda Stock On Friday? Benzinga

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth Business Wire

Takeda receives FDA approval for Vonvendi sBLA Pharmaceutical Business review -

Alpha-1 Antitrypsin Deficiency Market Research 2025-2035, Competitive Analysis of Grifols, CSL Behring, Takeda Pharmaceuticals, LFB Biotechnologies, GlaxoSmithKline, AstraZeneca, Merck, Pfizer - ResearchAndMarkets.com Business Wire

Drugmaker Takeda's CEO Weber to step down, raises profit forecast Reuters

Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nation’ Proposal BioSpace

Takeda continues stock plan for management in 2025 Investing.com

Takeda Targets Clinical Disparities in Psoriasis Research Dermatology Times

White & Case advises Takeda on divestment of assets to Hikma and Esteve White & Case LLP

Takeda plans drug launches and hiring for 2025 The Business Journals

The Escalator: Acadia Pharmaceuticals, Indivior, Takeda and more Medical Marketing and Media

Takeda files executive compensation report with SEC Investing.com

Takeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Studies TipRanks

Takeda CEO Christophe Weber to step down following prolonged drop in company shares statnews.com

Takeda’s Narcolepsy Drug Study Abstract Accidentally Published TipRanks

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business Citeline News & Insights

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 Business Wire

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan PR Newswire

Takeda’s in-house banking expansion into APAC flow – Deutsche Bank

Health Canada grants market authorisation to Takeda’s FRUZAQLA Pharmaceutical Technology

Takeda Pharmaceutical to invest $30bn in US over 5 years: CEO Nikkei Asia

Takeda Pharmaceutical Reports Mixed Financial Results for Q2 2025 TipRanks

Takeda taps Julie Kim to take over for retiring CEO Christophe Weber Fierce Pharma

10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia Business Wire

Japanese pharma company Takeda to conduct clinical trials in India soon Times of India

Breakthrough PV Drug Rusfertide Doubles Response Rates in Phase 3 Trial, ASCO Data Reveals Stock Titan

Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets BioSpace

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics Business Wire

Lexington biotech gets $200M upfront from Takeda for anemia drug The Business Journals

Takeda regains home rights to phase 3-stage depression drug from Neurocrine Fierce Biotech

Redefining healthcare innovation to benefit the whole patient Fast Company

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform Business Wire

Takeda's oral TYK2 inhibitor matches biologic efficacy drugdiscoverytrends.com

Takeda reports progress in narcolepsy type 1 treatment By Investing.com Investing.com Nigeria

Why Takeda no longer has an 'IT department' as part of the drug maker's digital and data transformation Fortune

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas Business Wire

Lupin gets U.S. FDA nod for generic of Takeda’s constipation drug The Hindu

Takeda’s First-in-Class Orexin Agonist Oveporexton Posts Stellar Phase III Results PharmiWeb.com

Takeda unveils new state-of-the-art warehouse in Belgium to enhance global supply operations Takeda Pharmaceuticals

Teva, Takeda sell generics joint venture in Japan to focus on innovative drugs Fierce Pharma

Aetna Sues Takeda Over Anti-Constipation Drug ‘Monopoly’ Bloomberg Law News

Takeda Unveils Pipeline Powerhouse: 6 Late-Stage Programs Target $20B Peak Revenue Potential Stock Titan

Takeda Reports Strong Q4 2024 Performance with 9.8% Revenue Growth, Driven by Oncology and Plasma-Derived Therapies BioSpectrum Asia

Takeda to launch dengue vaccine in India next year Times of India

Japan's Takeda raises full-year profit forecast amid restructuring Reuters

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook Business Wire

3 stories of crisis, action and putting patients first Takeda Pharmaceuticals

Seeing dengue up close drives vaccine researchers | Takeda Stories Takeda Pharmaceuticals

How Takeda Pharmaceuticals Accelerates Large-Scale Bioinformatics with AWS HealthOmics Amazon Web Services

Japan's Takeda to offload generic drug venture with Israel's Teva Nikkei Asia

Takeda is fourth big company to leave BIO since December statnews.com

Ex-Takeda employee sentenced for multi-million dollar fraud scheme MassLive